We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cyclosporiasis Detected in Mexico Travelers

By LabMedica International staff writers
Posted on 23 Aug 2017
Cyclosporiasis is an intestinal illness caused by the microscopic parasite Cyclospora cayetanensis. More...
People can become infected with Cyclospora by consuming food or water contaminated with the parasite.

People living or traveling in countries where cyclosporiasis is endemic may be at increased risk for infection. During the summers of 2015 and 2016, the UK experienced large outbreaks of cyclosporiasis in travelers returning from Mexico. As the source of the outbreaks was not identified, there is the potential for a similar outbreak to occur in 2017 and indeed 78 cases had already been reported by July 27, 2017.

Scientists working with Health Protection Scotland (Glasgow, UK) were was informed of cyclosporiasis among travelers returning from Mexico. Subsequently, cases were also detected among residents of England, Wales, Jersey and Isle of Man. Individuals were considered a probable case of cyclosporiasis if they had a sample date between 1 June and 28 October 2016 and travelled to Mexico in the previous 14 days, and if oocysts were identified in stool specimens by a diagnostic laboratory. Confirmed cases were probable cases confirmed microscopically by a national reference laboratory. Between June 1 and October 28, 2016, a total of 440 cases were reported in the UK, of which 289 (66%) were confirmed.

Food and travel histories were collected, and 359 (82%) cases reported recent travel history to Mexico, four had travelled to four different countries, two reported no overseas travel and travel history was unavailable for the other 75 cases. The epidemiological investigations demonstrated that 231 (64%) of the travelers had visited Mexico and had stayed in the Riviera Maya and Cancun regions often in all-inclusive hotels. Despite extensive descriptive epidemiological investigations in the UK, a formal analytical epidemiological study was not conducted and no specific vehicle was identified.

To improve laboratory testing, reminders were sent to diagnostic laboratories to consider testing for Cyclospora in cases where individuals had compatible symptoms and travel history. Discussions were also held among UK parasitology reference laboratories to share their confirmatory methodologies (fluorescence and stained microscopy and/or polymerase chain reaction), to review the usefulness of quantitative PCR for monitoring assay development and performance, and consider methods for genotyping and progression of whole genome sequencing.

The authors concluded that the recurring seasonal increase of cyclosporiasis cases is of public health importance due to the detrimental effect that this infection has on symptomatic cases, both during and following travel. Based on the previous UK cyclosporiasis outbreaks, they recommend other European countries to assess, and increase if necessary, Cyclospora laboratory testing and reporting capacity, increase cyclosporiasis risk awareness among travelers to Mexico, report cyclosporiasis cases early, and collaborate in outbreak investigations to identify possible sources and to assess the extent of the outbreak. The study was published in the journal Eurosurveillance.

Related Links:
Health Protection Scotland


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.